Comparison · NCT02128958-sae
CF102 vs Placebo Tablets of CF102: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CF102 vs Placebo Tablets of CF102: serious adverse events. Trial comparisons, record NCT02128958-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02128958-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.74 | 0.604 | 0.841 | wilson | |
| Risk in group 2 | 0.714 | 0.529 | 0.847 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0257 | -0.164 | 0.237 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.778 | 1.38 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.404 | 3.21 | log | |
| Number needed to harm, for one more participant with a serious adverse event on CF102 than on Placebo Tablets of CF102 | 38.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CF102 | CF102 25 mg capsules administered orally BID | 37 | 50 | EG000 |
| Group 2 | Placebo Tablets of CF102 | Placebo capsules administered orally BID | 20 | 28 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
AEs were recorded for each subject at the start of Cycle 1 Day 1 visit and followed to the 28-day Follow-Up Visit (28 days post End of Dosing) for up to 1 year/ Open-Label (OL) Follow-Up Visit (28 days post OL End of Dosing) for an average of 1 year. For observed toxicity thought to be at least possibly related to study drug was not resolved by the 28-day Follow-Up Visit/OL Follow-Up Visit, the subject was followed until the event resolved or stabilized, for an average of up to 24 months.
Source ClinicalTrials.gov
Trial
- Title
- Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
- NCT number
- NCT02128958
- Phases
- PHASE2
- Conditions
- Hepatocellular Carcinoma
- Interventions
- CF102, Placebo
- Lead sponsor
- Can-Fite BioPharma
- Results first posted
- 2021-12-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02128958?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02128958-sae